Monday, after the market close, shares of IceCure Medical ICCM surged by as much as 1,000% before pulling back. The Israel-based medical device maker aims to provide patients with treatment for cancerous tumors, and it looks like they are doing just that. Late Monday, the company announced successful studies pertaining to its kidney tumor treatment at a Urological Association conference in Israel. The stock is up more than 650% at the time of this writing.
What is Prosense? IceCure’s Prosense is a minimally invasive medical device that seeks to destroy tumors by freezing them in a process called cryoablation.
Who does Prosense help? The technology is looking to treat patients with…
